Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
inclacumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Caucasian Healthy volunteers | ACTIVE_COMPARATOR | - |
| Japanese Healthy volunteers | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| inclacumab | DRUG | single intravenous doses |
Inclusion Criteria: * Healthy male and female volunteers, 18 to 55 years of age, inclusive Healthy status as defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination * Japanese subjects must have Japanese p...
Inclacumab is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and remains in clinical development. The completed Phase 1 trial evaluated a single dose in Japanese and Caucasian healthy volunteers to assess its safety and pharmacokinetics.
Inclacumab is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company sponsored the Phase 1 clinical trial of the drug in healthy volunteers.
Inclacumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The single completed Phase 1 trial involved 62 healthy volunteers.
Inclacumab has one completed clinical trial, NCT01815827, titled "A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers." This Phase 1 study enrolled 62 participants in the United States and was completed.
No alternative names for inclacumab have been reported. It is identified by its single name in clinical trial records and development documentation.